CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines

On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted for expanded usage recommendation for Merck & Co Inc’s (NYSE:MRK) and Pfizer Inc’s (NYSE:PFE) pneumococcal conjugate vaccines.

The CDC panel has recommended lowering the pneumococcal vaccination age from 65 to 50 years old.

“ACIP’s vote to expand adult pneumococcal vaccination to now include all adults aged 50 and older marks an important milestone in Pfizer’s long-standing commitment to reducing the burden of this life-threatening disease,” Pfizer’s chief medical affairs officer for global vaccines and antivirals, said Luis Jodar.

Also Read: Bacterial Infections Vaccine Developer ...